Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Effectiveness, Acceptability and Feasibility of a Communication and Care Coordinator (CCC) Model in Facilitating Serious Illness Communication (SIC) and Care in Patients With Cancer (CCC-Cancer)

5 novembre 2026 mis à jour par: National Cancer Centre, Singapore

Evaluating the Effectiveness, Acceptability and Feasibility of a Communication and Care Coordinator (CCC) Model in Facilitating Serious Illness Communication (SIC) and Care in Patients With Cancer

The goal of this clinical trial is to evaluate the communication and care coordinator (CCC) model in a national cancer institute and assess the utility of the model in facilitating serious illness communication (SIC) and care for patients with cancer.

The study aims are:

  • To assess the effectiveness of the CCC model in improving patient outcomes.
  • To assess the effectiveness of the CCC model in increasing rates of SIC and advance care planning (ACP) record documentation.
  • To assess the acceptability of the CCC model to patients and clinicians.
  • To evaluate the feasibility of implementing a CCC model in oncology care.

Researchers will compare results from the CCC intervention arm and usual care arm, to see if the CCC model can help improve patient outcomes and facilitate SIC between patients and clinicians.

Patient participants will:

  • Follow the assignment of their clinician, who will be assigned randomly to either the usual care group or the intervention group.
  • Be assigned a CCC and receive 6 CCC sessions over the course of 3 months (if assigned to CCC intervention arm).
  • Complete 3 study assessment visits at baseline, Week 6, and 3 months
  • Be invited to a one-time interview to share their study experience (optional, if selected and if in CCC intervention arm).

Aperçu de l'étude

Statut

Recrutement

Les conditions

Intervention / Traitement

Description détaillée

Timely SIC may facilitate earlier preferred plan of care documentation and improve patients' sense of peacefulness, hopefulness, and connectedness with their clinicians. The primary goal of the study is to evaluate the CCC model in a national cancer institute and assess the utility of the model in facilitating SIC and care for patients with cancer through a stepped wedge cluster randomized trial. This approach delivers crucial, empirical insights into how SIC can be efficiently and effectively delivered and potentially allow larger scale implementation and dissemination of the CCC model in Singapore, as an effective model for delivering patient support and facilitating patient-clinician communication in patients with advanced cancer.

Type d'étude

Interventionnel

Inscription (Estimé)

560

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Sauvegarde des contacts de l'étude

  • Nom: Benton PT TAM, MSc

Lieux d'étude

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

21 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

Patient Participants

  • Aged 21 and above
  • Diagnosed with (a) advanced cancer (stage 3 or 4) or (b) non-advanced cancer, but at high risk of recurrence
  • Able to speak English or Chinese, irrespective of race

Clinicians

  • Oncologists who are at least of designation of associate consultant and above in NCCS

Exclusion Criteria:

Patient Participants

  • Disoriented and thus not able to sign informed consent
  • Diagnosed with untreated hearing or visual loss or psychiatric illness
  • Active suicidal ideation

Clinicians

  • Overseas/not practising in Singapore for a significant amount of time

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Recherche sur les services de santé
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Seul

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: CCC Intervention Arm

Each participant will be assigned a CCC and receive 6 CCC sessions over the course of 3 months.

CCC sessions will be on exploring participant's illness journey thus far, their concerns, values and priorities.

Aucune intervention: Usual Care Arm

Each participant will continue to be followed by the oncologist and receive usual care but will not receive CCC intervention.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Communication Quality
Délai: Baseline, Week 6 after Baseline, and 3 months Post Enrolment.

Feeling Heard and Understood Survey (FHU) is a validated 4-item scale that has been used in palliative care to measure effectiveness of the SIC conversations and the value of the therapeutic relationship between the care team and the patient. The lowest possible score is 0 and the highest possible score is 16, with a higher score indicating that the care team listens well, respects patient's needs, and provides clear communication.

Baseline, Week 6 after Baseline, and 3 months Post Enrolment.
Quality of Life per FACT-G7
Délai: Baseline, Week 6 after Baseline, and 3 months Post Enrolment.

Functional Assessment of Cancer Therapy-General-7 Item version (FACT-G7) is a 7-item questionnaire designed to quickly and effectively capture the most relevant issues to cancer. FACT-G7 scores could potentially range from 0-28, with a higher score indicating a better quality of life.

Baseline, Week 6 after Baseline, and 3 months Post Enrolment.
Health Utility
Délai: Baseline, Week 6 after Baseline, and 3 months Post Enrolment.

EuroQOL Group 5-Dimension (EQ-5D-5L) contains a 5-item descriptive system measuring 5 dimensions: mobility, self-care, usual activities, pain/ discomfort, anxiety/ depression; a visual analogue scale (VAS) measuring overall health status. EQ-5D Index Value (Utility Score) ranges from 0 to 1.0 with higher value indicating better health-related quality of life. The VAS ranges from 0 to 100, with higher scores reflecting better self-rated health.

Baseline, Week 6 after Baseline, and 3 months Post Enrolment.
Spiritual Well-Being
Délai: Baseline, Week 6 after Baseline, and 3 months Post Enrolment.

Functional Assessment of Chronic Illness Therapy - Spiritual Well-Being 12 Item Scale (FACIT-Sp-12) is a validated 12-item survey that is commonly used in the palliative care setting. It has 3 subscales (meaning, peace and faith). Scores in each subscale can potentially range from 0-16 and the total scores can range from 0-48. A higher score indicates greater spiritual well-being, better ability to find purpose in life and drawing comfort from spiritual resources.

Baseline, Week 6 after Baseline, and 3 months Post Enrolment.
Healthcare Utilization - Rate of Unplanned Acute Hospital Utilization
Délai: From Study Enrolment to 3 months Post Enrolment.

The rate of unplanned acute hospital utilization through the emergency department during the study will be collected.

From Study Enrolment to 3 months Post Enrolment.
Healthcare utilization - Length of hospital stay
Délai: From Study Enrolment until Date of Death, up to 3 years.

Data on the length of stay in hospital (bed days) will be collected.

From Study Enrolment until Date of Death, up to 3 years.
Healthcare utilization - Hospital Bill
Délai: From Study Enrolment until Date of Death, up to 3 years.

Data on hospital bill size will be collected.

From Study Enrolment until Date of Death, up to 3 years.
Healthcare utilization - Type of oncological treatment
Délai: From 3 months prior to study enrolment until 3 months after study enrolment.

Data on the type of oncological treatment used will be collected.

From 3 months prior to study enrolment until 3 months after study enrolment.
Healthcare utilization - Chemotherapy usage (line)
Délai: From Study Enrolment until Date of Death, up to 3 years.

Data on the line of chemotherapy (first, second or third or subsequent (fourth and onwards)) will be collected.

From Study Enrolment until Date of Death, up to 3 years.
Healthcare utilization - Intensive care unit visit
Délai: From Study Enrolment until Date of Death, up to 3 years.

Data on the number of intensive care unit visits will be collected.

From Study Enrolment until Date of Death, up to 3 years.
Healthcare utilization - Length of intensive care unit visit
Délai: From Study Enrolment until Date of Death, up to 3 years.

Data on the length of intensive care unit visits will be collected.

From Study Enrolment until Date of Death, up to 3 years.
Healthcare utilization - High dependency unit visit
Délai: From Study Enrolment until Date of Death, up to 3 years.

Data on the number of high dependency unit visits will be collected.

From Study Enrolment until Date of Death, up to 3 years.
Healthcare utilization - Length of high dependency unit visit
Délai: From Study Enrolment until Date of Death, up to 3 years.

Data on the length of high dependency unit visits will be collected.

From Study Enrolment until Date of Death, up to 3 years.
Healthcare utilization - Location of death
Délai: From Study Enrolment until Date of Death, up to 3 years.

Data on the location of death will be collected.

From Study Enrolment until Date of Death, up to 3 years.

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Acceptability - Satisfaction
Délai: 3 months Post Enrolment.

Client satisfaction survey is a 4-item, 4-point scale survey in which patients provide ratings on their satisfaction with the intervention, and their views on its relevance, timeliness, and impact. It has been validated in research studies in the outpatient setting around mental health support. Score can range from 4-16, with a higher score indicating greater client satisfaction.

3 months Post Enrolment.
Feasibility - Approach-to-Enrolment Rates
Délai: From Commencement of Study Recruitment till the End of Recruitment, up to 24 months.

Approach-to-enrolment rates - where feasibility is defined that at least 60% of those patients approached could be enrolled into the study.

From Commencement of Study Recruitment till the End of Recruitment, up to 24 months.
Feasibility - Patient Retention Rate
Délai: Baseline through Study Completion, estimated as up to 3 years.

Patient retention rate - where feasibility is defined that at least 80% of enrolled patients will be able to participate in the study for the planned study duration (3 months).

Baseline through Study Completion, estimated as up to 3 years.
Effectiveness - SIC and ACP documentation
Délai: From Commencement of Study Enrollment through Study Completion, estimated as up to 3 years

The number of SIC and ACP documentation per clinician per enrolled patient during the study duration will be tracked during the intervention period(s) and during the control period(s). Clinical notes will also be read to evaluate if there was relevant documentation by clinician on SIC related issues.

From Commencement of Study Enrollment through Study Completion, estimated as up to 3 years
Effectiveness - Time spent
Délai: From Commencement of Study Enrollment through Study Completion, estimated as up to 3 years

Time spent by CCC in this model and estimated time spent by clinicians on SICs will be collected.

From Commencement of Study Enrollment through Study Completion, estimated as up to 3 years
Acceptability - Clinician experience
Délai: At end of intervention period (28th month).

Clinicians will be surveyed using a modified version of the Clinician Experience Survey (CES). The original CES was developed by Ariadne Labs for the purposes of assessing clinicians perceived feasibility and barriers in engaging patients in SIC. The researchers will modify the CES to form a 4-item scale (score range 4-16), with a higher score indicating greater clinicians' satisfaction with the CCC intervention.

At end of intervention period (28th month).

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Les enquêteurs

  • Chaise d'étude: Shirlyn NEO Hui Shan, MD, PhD, National Cancer Centre, Singapore

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Publications générales

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

5 novembre 2026

Achèvement primaire (Estimé)

30 juin 2028

Achèvement de l'étude (Estimé)

30 juin 2029

Dates d'inscription aux études

Première soumission

21 juillet 2026

Première soumission répondant aux critères de contrôle qualité

24 juillet 2026

Première publication (Réel)

29 juillet 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

10 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

5 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Termes MeSH pertinents supplémentaires

Autres numéros d'identification d'étude

  • 2026-1239

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .